Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.
China has made significant strides in drug development over the past two decades, transitioning from being a producer of generic drugs to a…
2024 was a year of breakthroughs in cancer care, research and knowledge at Ohio State, where oncology experts look ahead to opportunities to innovate in…
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory…
An abstract is unavailable.
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory…
Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for the treatment of pediatric patients with steroid-refractory acute graft-vs-host…
Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of rememstemcel-L in pediatric SR-aGVHD.
If you’re worried about your risk for breast cancer, you’re not alone. That’s especially true if you have a family history of the disease. But…
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
